Bafna Pharmaceuticals Limited has submitted to the Exchange, Outcome of the Board Meeting held on 26/05/2025 along with the Audited Financial Results for the Quarter and Year ended March 31, 2025.
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bafna Pharmaceuticals Limited has submitted the outcome of its board meeting held on May 26, 2025, along with the audited financial results for the quarter and full year ended March 31, 2025. The filing was made to the NSE as required under listing regulations. No specific financial figures, dividend declarations, or auditor observations are available from the headline alone. The audited status indicates the full-year numbers have been certified by the statutory auditors after the financial year-end process.
This is a routine regulatory filing that makes the company's full-year and Q4 FY25 results officially available to the public. Shareholders and investors should review the detailed results document for actual revenue, profit, and auditor commentary to assess the stock's direction.